Drug Interaction Report

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir. According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.

MANAGEMENT: The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided. If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended. Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.

Consumer information for this interaction is not currently available.

MONITOR: Smoking and alcohol consumption during therapy with vadadustat may increase the risk of gastrointestinal erosions. Serious erosions, including gastrointestinal bleeding and the need for red blood cell transfusions, have been reported during vadadustat clinical trials. Patients with a history of gastrointestinal erosion, peptic ulcer disease, and current tobacco smokers and alcohol drinkers may be at higher risk of gastrointestinal injury.

MANAGEMENT: Caution is advised if vadadustat is prescribed to current tobacco smokers or alcohol drinkers. Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, hematemesis, trouble swallowing, chest or throat pain, and/or black, tarry stools.

Information for this minor interaction is available on the professional version.